Skip to main content
Antares Vision logo

Antares Vision — Investor Relations & Filings

Ticker · AV ISIN · IT0005366601 LEI · 815600807B866042D307 XMIL Manufacturing
Open in API
Filings indexed 826 across all filing types
Latest filing 2023-11-13 Interim / Quarterly Rep…
Country IT Italy
Listing XMIL AV

About Antares Vision

https://www.antaresvision.com/

Antares Vision Group provides technology solutions focused on product quality control and supply chain transparency. The company develops, produces, and maintains integrated systems for inspection, track & trace, and smart data management. Its portfolio includes visual inspection machines designed to ensure product quality and integrity on production lines, as well as comprehensive hardware and software solutions for serialization to meet global regulatory compliance. Leveraging technologies such as Artificial Intelligence (AI), the group offers a data intelligence platform to enhance line efficiency and production quality. Antares Vision Group serves various sectors, primarily life sciences (pharmaceuticals, medical devices) and Fast-Moving Consumer Goods (FMCG), enabling end-to-end traceability and data-driven factory management.

Recent filings

Filing Released Lang Actions
IL CDA APPROVA I RICAVI CONSOLIDATI AL 30 SETTEMBRE 2023
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial report for the first nine months (9M) and third quarter (3Q) of 2023 for Antares Vision S.p.A. It contains comprehensive financial data, including consolidated revenue, order intake, geographic breakdowns, and business model analysis, along with management commentary on performance and future outlook. It is not a mere announcement or a short summary, but a substantive financial report, fitting the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-13 Italian
MODALITÀ E RAPPORTO DI ESERCIZIO DEI WARRANT ANTARES VISION
Share Issue/Capital Change Classification · 99% confidence The document is a press release ("COMUNICATO STAMPA") detailing the calculation of the average monthly price for Antares Vision warrants for October 2023 and concluding that the exercise of warrants for November 2023 is not possible because the average price (€2.8883) is below the strike price (€9.50). This announcement relates to the terms and conditions of financial instruments (warrants) and their potential conversion/exercise, which directly impacts the company's capital structure or financing terms. This fits best under 'Capital/Financing Update' (CAP), as it is a direct update on the status of a financing instrument. It is not a general earnings release (ER), a full financial report (IR/10-K), or a dividend notice (DIV). Since it is a specific update on the mechanics of a financing instrument, CAP is the most appropriate classification over the general 'RNS'.
2023-11-02 Italian
PROCEDURES AND EXERCISE RATIO OF ANTARES VISION WARRANTS
Capital/Financing Update Classification · 95% confidence The document is a press release announcing specific procedural details regarding the exercise ratio and procedures for Antares Vision Warrants based on the October 2023 average monthly price. This announcement directly relates to the company's capital structure and financing instruments (warrants). While it touches upon share capital changes (which could suggest SHA), the core purpose is to communicate the status and rules governing the exercise of these financial instruments, which is best classified under Capital/Financing Update (CAP). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). It is a specific update on a financing mechanism.
2023-11-02 English
PROCEDURES AND EXERCISE RATIO OF ANTARES VISION WARRANTS
Capital/Financing Update Classification · 95% confidence The document is a 'PRESS RELEASE' dated October 2, 2023, announcing the 'PROCEDURES AND EXERCISE RATIO OF ANTARES VISION WARRANTS' based on the September 2023 Average Monthly Price. This announcement details the status of warrants (whether they can be exercised or not) and mentions the resulting stability of the share capital and outstanding warrants. This type of specific financial instrument update, which is not a full financial report (10-K, IR), earnings release (ER), or dividend notice (DIV), fits best under Capital/Financing Update (CAP) as it directly relates to the company's capital structure instruments (warrants). Since it is a specific announcement about a financing instrument's terms, CAP is the most precise fit over the general 'RNS' fallback.
2023-10-02 English
MODALITÀ E RAPPORTO DI ESERCIZIO DEI WARRANT ANTARES VISION
Share Issue/Capital Change Classification · 99% confidence The document is titled "COMUNICATO STAMPA" (Press Release) and specifically discusses the exercise modalities and report for Antares Vision Warrants. It details the calculation of the Monthly Average Price for September 2023 and concludes that the warrants cannot be exercised in October 2023 because the average price was below the strike price. This is a specific corporate action update related to financial instruments (warrants) and capital structure, but it is not a standard periodic report (like 10-K or IR) or a general financing announcement (CAP). It is a specific notice regarding the status of outstanding warrants. Given the options, this type of specific, non-periodic corporate action announcement related to capital instruments fits best under Capital/Financing Update (CAP) or, if it were a general regulatory notice, RNS. Since it directly concerns the terms and exercise of capital instruments, CAP is the most precise fit, although it is a very specific type of update. It is not a general earnings release (ER) or a dividend notice (DIV). Given the focus on warrant exercise conditions, CAP is the most appropriate classification.
2023-10-02 Italian
Emidio Zorzella, Presidente di Antares Vision Group, al Panel Salute del Summit "Business & Investment per l’Africa SubSahariana" delle Nazioni Unite
Regulatory Filings Classification · 95% confidence The document is titled "COMUNICATO STAMPA" (Press Release) and details the participation of the company's President in a UN Summit panel regarding combating counterfeit drugs in Africa. It announces an event and quotes key figures. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a general announcement about company activities, participation in an event, and general corporate news that doesn't fit the highly specific categories (like DIRS, DIV, CAP, etc.), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings), as it functions as a broad corporate disclosure.
2023-09-25 Italian

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.